Sana Biotechnology (NASDAQ:SANA) Shares Down 3.3% – Time to Sell?

Sana Biotechnology, Inc. (NASDAQ:SANA) shares dropped 3.3% during mid-day trading on Wednesday . The stock traded as low as $3.96 and last traded at $3.9450. Approximately 275,692 shares changed hands during mid-day trading, a decline of 95% from the average daily volume of 5,536,168 shares. The stock had previously closed at $4.08.

Analyst Ratings Changes

SANA has been the subject of a number of recent analyst reports. Wedbush upped their price target on shares of Sana Biotechnology from $5.00 to $6.00 and gave the stock an “outperform” rating in a report on Friday, November 7th. HC Wainwright reduced their target price on shares of Sana Biotechnology from $11.00 to $9.00 and set a “buy” rating on the stock in a report on Friday, November 7th. Weiss Ratings reissued a “sell (e+)” rating on shares of Sana Biotechnology in a research note on Monday. Citigroup reiterated an “outperform” rating on shares of Sana Biotechnology in a report on Thursday, October 30th. Finally, Wall Street Zen upgraded shares of Sana Biotechnology from a “sell” rating to a “hold” rating in a research report on Saturday, December 20th. Eight equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $8.33.

Sana Biotechnology Stock Performance

The stock’s 50 day moving average is $4.43 and its 200 day moving average is $3.94. The company has a market capitalization of $1.06 billion, a PE ratio of -4.12 and a beta of 1.95.

Sana Biotechnology (NASDAQ:SANA) last posted its earnings results on Thursday, November 6th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.18) by $0.03. On average, equities research analysts forecast that Sana Biotechnology, Inc. will post -1.16 EPS for the current fiscal year.

Hedge Funds Weigh In On Sana Biotechnology

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Marex Group plc purchased a new stake in shares of Sana Biotechnology during the second quarter valued at approximately $10,423,000. Vanguard Group Inc. increased its position in Sana Biotechnology by 19.9% during the third quarter. Vanguard Group Inc. now owns 9,128,973 shares of the company’s stock valued at $32,408,000 after acquiring an additional 1,517,474 shares during the last quarter. JPMorgan Chase & Co. raised its position in Sana Biotechnology by 180.8% in the third quarter. JPMorgan Chase & Co. now owns 2,135,444 shares of the company’s stock worth $7,581,000 after acquiring an additional 1,375,029 shares during the period. Baillie Gifford & Co. lifted its position in Sana Biotechnology by 13.6% during the third quarter. Baillie Gifford & Co. now owns 11,436,503 shares of the company’s stock valued at $40,600,000 after purchasing an additional 1,371,775 shares in the last quarter. Finally, Corient Private Wealth LLC grew its holdings in Sana Biotechnology by 264.7% during the second quarter. Corient Private Wealth LLC now owns 1,136,000 shares of the company’s stock valued at $3,101,000 after purchasing an additional 824,505 shares during the period. Institutional investors own 88.23% of the company’s stock.

Sana Biotechnology Company Profile

Sana Biotechnology is a clinical-stage biopharmaceutical company focused on the development of engineered cells as medicines with the goal of treating a broad range of diseases. The company applies advanced gene editing and gene delivery technologies to create next-generation cell therapy products for oncology, genetic disorders and other serious diseases. By leveraging both ex vivo and in vivo approaches, Sana aims to repair or replace damaged cells and restore healthy tissue function.

The company’s core platform integrates proprietary gene writing capabilities alongside established gene editing tools such as CRISPR–Cas9.